Core Viewpoint - The stock of药捷安康-B (02617) has experienced a significant decline, dropping over 5% and more than 11% in the previous day, indicating market concerns regarding its recent equity placement and pricing strategy [1] Group 1: Stock Performance - As of the latest update, the stock is trading at 95.1 HKD with a trading volume of 82.17 million HKD [1] - The stock has seen a decline of over 5% in the current trading session following a previous drop of more than 11% [1] Group 2: Equity Placement - The company announced a placement of 2.1 million shares, which represents approximately 0.69% of the enlarged H shares and about 0.53% of the total issued shares [1] - The placement price is set at 92.85 HKD per share, reflecting a discount of approximately 17.98% compared to the closing price of 113.2 HKD on January 13 [1] - The expected net proceeds from the placement are around 190 million HKD [1] Group 3: Use of Proceeds - Approximately 60% of the funds raised will be allocated to clinical trials for the core product Tinengotinib, specifically for its use in treating cholangiocarcinoma (CCA) in China [1] - About 30% of the proceeds will be directed towards the development of other products, including TT-00973, TT-01488, and other molecules [1] - The remaining 10% is intended for working capital and general corporate purposes [1]
药捷安康-B续跌超5% 昨日重挫逾11% 公司拟折让近18%配股筹资